NasdaqGS - Nasdaq Real Time Price USD

Akoya Biosciences, Inc. (AKYA)

Compare
2.1200 -0.0400 (-1.85%)
At close: November 21 at 4:00 PM EST
2.1200 0.00 (0.00%)
After hours: November 21 at 4:20 PM EST
Loading Chart for AKYA
DELL
  • Previous Close 2.1600
  • Open 2.1900
  • Bid 1.6000 x 200
  • Ask 2.6800 x 200
  • Day's Range 2.0900 - 2.2500
  • 52 Week Range 1.8800 - 6.3100
  • Volume 135,361
  • Avg. Volume 153,348
  • Market Cap (intraday) 105.074M
  • Beta (5Y Monthly) 1.35
  • PE Ratio (TTM) --
  • EPS (TTM) -1.1600
  • Earnings Date Nov 14, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.62

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

www.akoyabio.com

330

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AKYA

View More

Performance Overview: AKYA

Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AKYA
56.56%
S&P 500
24.72%

1-Year Return

AKYA
51.71%
S&P 500
30.82%

3-Year Return

AKYA
83.55%
S&P 500
26.62%

5-Year Return

AKYA
91.85%
S&P 500
42.13%

Compare To: AKYA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AKYA

View More

Valuation Measures

Annual
As of 11/20/2024
  • Market Cap

    107.06M

  • Enterprise Value

    156.08M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.23

  • Price/Book (mrq)

    7.85

  • Enterprise Value/Revenue

    1.80

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -64.74%

  • Return on Assets (ttm)

    -18.09%

  • Return on Equity (ttm)

    -128.20%

  • Revenue (ttm)

    93.22M

  • Net Income Avi to Common (ttm)

    -60.35M

  • Diluted EPS (ttm)

    -1.1600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    45.22M

  • Total Debt/Equity (mrq)

    380.68%

  • Levered Free Cash Flow (ttm)

    -34.91M

Research Analysis: AKYA

View More

Company Insights: AKYA

Research Reports: AKYA

View More

People Also Watch